News

Purespring Showcases Breakthrough Research at Kidney Week 2025

Purespring Showcases Breakthrough Research at Kidney Week 2025

Purespring's Groundbreaking Posters at ASN Kidney Week 2025

Purespring Therapeutics is excited to announce that it will showcase groundbreaking research during the American Society of Nephrology (ASN) Kidney Week 2025. This extraordinary event is set to take place from November 5 to 9, 2025, in Houston, Texas. Attendees can look forward to three scientifically rich posters focused on advancing nephrology and gene therapies aimed at preserving kidney function.

Phase I/II Trial of PS-002

The first poster highlights the study design and methodology of Purespring's Phase I/II trial for PS-002, an innovative AAV-based gene therapy targeting complement factor I delivery to podocytes in patients suffering from IgA nephropathy (IgAN). This pioneering approach has the potential to address complement-driven glomerular conditions directly where the disease occurs, while maintaining systemic complement activation. A single dose of PS-002 is anticipated to provide long-term benefits, enabling podocytes to produce therapeutic factors locally when needed.

Engaging Patients and Caregivers

Feedback on Gene Therapy Study Concepts

The second poster focuses on insights gathered from feedback sessions involving IgAN patients and their caregivers in both the US and the UK. Conducted in collaboration with the IgA Nephropathy Foundation and the National Institute for Health and Care Research, these sessions aimed to refine clinical trial design for future therapies, including PS-002. The enthusiasm expressed for a simplified, 'one-and-done' treatment model illustrates a strong demand for innovative approaches to gene therapy in nephrology.

Real-World Epidemiological Insights

Epidemiological Data on NPHS2 Variants

Purespring also joins forces with the University of Bristol on the third poster, which presents comprehensive data on NPHS2 pathogenic variants derived from the analysis of over 1.2 million genomes. This research aims to estimate the frequency of pathogenic genotypes across various populations, including the US, UK, Europe, and Japan. Additionally, the study provides insights into how these variants influence disease manifestation and progression in conditions such as focal segmental glomerulosclerosis (FSGS) and steroid-resistant nephrotic syndrome (SRNS).

Purespring's Commitment to Innovation

Purespring is actively pushing the boundaries in precision nephrology with its commitment to developing transformative genetic therapies. The company’s GlomThera™ platform allows for direct genetic therapy delivery to the affected kidney cells, representing a novel route for intervening in kidney diseases. Purespring's approach is not only about addressing existing conditions but is focused on reshaping the future of kidney health.

Looking Ahead

In a significant development, Purespring recently secured UK Clinical Trial Authorisation for its Phase I/II trial of PS-002, marking a pivotal step forward in its mission to improve outcomes for patients with IgAN. This authorization follows earlier achievements, including obtaining IND clearance from the FDA, which underscores the company's dedication to rigorous clinical standards and findings.

For more updates and detailed information about Purespring, including ongoing and future initiatives, stay connected through their official website and LinkedIn page. By focusing on unmet medical needs within nephrology, Purespring aims to inform and empower patients, healthcare professionals, and the broader community about the advancements in kidney disease treatments.

Frequently Asked Questions

What is the significance of Purespring's presentation at Kidney Week 2025?

Purespring's presentations at Kidney Week highlight groundbreaking research in gene therapy for kidney diseases, showcasing their commitment to innovation and patient engagement.

What are the key focuses of Purespring's research?

The key focuses include gene therapy design, patient feedback on clinical trials, and real-world epidemiological data on nephrology conditions.

Who are the main presenters at the poster sessions?

Fredrik Erlandsson, the Chief Medical Officer of Purespring, will present the key findings during the poster sessions.

What is PS-002 and its role in nephrology?

PS-002 is an AAV-based gene therapy designed to deliver the complement factor I to podocytes, targeting IgA nephropathy and helping to manage the disease effectively.

How is Purespring addressing unmet needs in kidney disease treatment?

Purespring is developing innovative, patient-centered therapies aimed at modifying disease progression, offering new hope to patients with kidney conditions.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Freedom Debt Relief Earns Service Recognition in 2026

Updated Category News Views 143

A Service Badge Carries Weight in a Rough Business Debt settlement is not a business where a pleasant phone voice alone gets the job done. People arrive carrying unsecured balances, anxiety, and usually a fair amount of distrust. That is why CNBC Select naming Freedom Debt Relief its “Best for Customer Service” is more meaningful than the usual chest-thumping...

Continue Reading
AT&T's Dec. 8 UBS Chat Puts Stankey's Updates on Watch

Updated Category News Views 0

A Small Slot With a Big Audience A calendar entry can still matter when the man holding the microphone runs AT&T. John Stankey, AT&T chairman and chief executive, is scheduled for a fireside chat at the UBS Global Media and Communications Conference on Tuesday, Dec. 8, beginning at 8:15 a.m. Eastern time. The company says the event will be webcast live through its...

Continue Reading
Zesty Takes Kubernetes Cost Control Into GPU Territory

Updated Category News Views 73

GPU waste has become the sort of cloud bill nobody wants to explain upstairs. A company buys scarce, expensive accelerators for AI work, then discovers that real workloads do not politely consume resources in neat, permanent blocks. Demand jumps, memory needs shift, and somebody either over-allocates to avoid trouble or under-allocates and gets ugly out-of-memory...

Continue Reading
Lennar Lawsuit Puts Land-Light Claims Under a Microscope

Updated Category News Views 65

Three ugly selloffs, a murky land-bank story, and a fresh securities complaint have turned Lennar into the sort of holding that makes shareholders reread every footnote. The lawsuit is not a verdict, and the allegations remain unproven, but the timeline is nasty enough that investors in NYSE:LEN should not shrug it off as ordinary housing-cycle turbulence. The Dates...

Continue Reading
Allstate's October Cat Loss Lands at $232 Million Net

Updated Category News Views 40

October’s weather bill arrived without much poetry: $232 million in estimated catastrophe losses at Allstate. Reported on November 19, that figure falls to $184 million after tax, and it deserves a clear-eyed read rather than the usual insurance-stock theatrics. A single monthly catastrophe tally is not a verdict on the company, but it is absolutely part of the...

Continue Reading
Intel Investors Face January 12 Lead Plaintiff Deadline

Updated Category News Views 41

A Narrow Calendar Window Has Opened Intel holders have another legal deadline to put on the fridge, and this one is not a casual housekeeping item. A securities class action has been filed in the Northern District of California on behalf of investors who bought or acquired Intel shares between July 23, 2026, and October 29, 2026. The deadline to seek appointment as lead...

Continue Reading
A. O. Smith's Sustainability Scorecard Has Real Teeth

Updated Category News Views 65

Numbers finally showed up wearing work boots in A. O. Smith’s latest sustainability report. The company says it beat every one of its three environmental targets, and the gaps were not the sort of rounding-error victories corporate communications teams love to polish until they shine. For investors following NYSE:AOS, that deserves a look—not a standing ovation, but a...

Continue Reading
Cooperate Marketing Lands 318th on Deloitte Fast 500

Updated Category News Views 49

A 199% revenue jump over three years will get my attention before any shiny award logo does. Cooperate Marketing says it grew that much from 2022 through 2025, enough to place No. 318 on Deloitte's 2026 Technology Fast 500 list. For a privately held Chicago marketing-technology outfit, that is a legitimate operating milestone, not just another ribbon to pin on the company...

Continue Reading
Automotive Laminates: Small Market, Real EV Leverage

Updated Category News Views 159

Cabin trim has become a surprisingly serious battleground, and that is the whole point of this automotive laminates story. Nobody buys a vehicle because somebody bragged about a multilayer film behind the door panel. Yet the materials under the fingertips, beneath the carpet, and around the dashboard increasingly decide whether an interior feels cheap, quiet, durable, or...

Continue Reading
Shenzhen Three-Way Summit Puts Stability to the Test

Updated Category News Views 130

Three nuclear powers sharing a room in Shenzhen is the sort of headline that makes every risk desk sit upright, even when the paperwork remains thin. CGTN reports that Chinese President Xi Jinping, Russian President Vladimir Putin and U.S. President Donald Trump met on November 19, 2026, in an unprecedented trilateral summit and issued a Declaration toward Peace. That is...

Continue Reading

Top 5 Most Recently Viewed Articles

Top Wealth Group Holding Limited Successfully Completes $10.8M Offering

Updated Category News Views 79

Top Wealth Group Holding Limited's Successful Public Offering Top Wealth Group Holding Limited (NASDAQ: TWG), a prominent player in the luxury food sector, has recently announced the successful closure of its public offering. The company offered a total of 27 million ordinary shares at a price of $0.40 each, resulting in gross proceeds of approximately $10.8 million...

Continue Reading
BlackRock's Innovative LifePath Paycheck™ Reaches $16B Milestone

Updated Category News Views 619

BlackRock’s LifePath Paycheck™ Achieves Significant Growth Recently, BlackRock announced a significant achievement in the realm of retirement planning. The LifePath Paycheck™, a target-date investment solution designed to provide guaranteed lifetime income, has reached an impressive $16 billion in assets under management (AUM). This innovative strategy is shaping...

Continue Reading
MYR Group to Connect with Investors at Upcoming Conference

Updated Category News Views 139

MYR Group Inc. at D.A. Davidson Conference MYR Group Inc. (“MYR Group”) (NASDAQ: MYRG), a prominent holding company specializing in electrical contracting, is gearing up to attend the D.A. Davidson 24th Annual Diversified Industrials & Services investor conference. This exciting event allows MYR Group to engage with institutional investors and industry leaders,...

Continue Reading
Regular Dividend Announcement for TDb Split Corp's Equity Shares

Updated Category News Views 267

TDb Split Corp. Announces Monthly Dividend for Shareholders In a recent announcement, TDb Split Corp. has confirmed its monthly distribution for shareholders. For each Class A share, the dividend is set at $0.05000, which translates to an annualized figure of $0.60. Meanwhile, holders of Priority Equity shares will receive $0.05833, or $0.700 on an annual basis. These...

Continue Reading
Exploring Wells Fargo's Recent Options Activity

Updated Category News Views 338

Exploring Wells Fargo's Recent Options Activity Investors with significant resources are displaying a bullish outlook on Wells Fargo (WFC). The actions of these investors could provide valuable insights for retail traders looking to navigate the market effectively. Today, unusual trading patterns emerged in options history, raising curiosity. Although we cannot confirm...

Continue Reading